AccScience Publishing / CP / Volume 7 / Issue 4 / DOI: 10.36922/CP025280043
Submit to CP
Cite this article
2
Download
37
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

Innovative approach in ovarian cancer treatment targeting IL2, TNF-Α, HSP70-90, EGF, and MMP2-9

Gul Zaib1,2* ,  Rehman Rashid2 ,  Haleema Saadia3
Show Less
1 Institute of Molecular Biology and Biotechnology (IMBB), The University of Lahore, The University of Lahore, Lahore, Punjab, Pakistan
2 Department of School of Pain and Regenerative Medicine (SPRM), Faculty of Sciences, The University of Lahore, Lahore, Punjab, Pakistan
3 Department of Biochemistry, Islam Medical and Dental College, Sialkot, Punjab, Pakistan
CP 2025, 7(4), 69–85; https://doi.org/10.36922/CP025280043
Received: 3 July 2025 | Revised: 19 September 2025 | Accepted: 9 December 2025 | Published online: 31 December 2025
© 2025 by the Author(s).. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
XML
Cite
Abstract

Because of its high death rate and intrinsic resistance to conventional treatment approaches, ovarian cancer remains a formidable challenge. Critical proteins, such as IL2, TNF-α, HSPs, EGF, and MMPs, have been made clear by recent advances in molecular biology and could be effective targets for therapeutics. Tetrahydrocannabinol (THC), Cannabinol, Elasterol, and 2-Methylenecholestan-3-ol are a few of the substances that have shown promise in influencing these particular targets. Ultimately, this study aims to develop novel approaches for the treatment of ovarian cancer by evaluating the therapeutic efficacy of 2-methylcholestan-3-ol, elastrol, THC, and cannabinol in the modulation of IL2, TNF-α, HSPs, EGF, and MMPs. In-silico assays were conducted by utilizing different bioinformatics databases to check ate potential therapeutic agent for the treatment of Ovarian cancer. Molecular docking analysis, protein ligand complexes, Swiss ADMA, Toxicity Prediction are the key Components steps of this study. This research highlights the potential of THC, CBD, elastrol, and 2-methylcholestan-3-ol in influencing key proteins linked to the development of ovarian cancer. According to these findings, these substances might be included in novel therapeutic strategies, opening up a promising avenue for improving ovarian cancer treatment. This study shows clear ability to modify the target proteins was demonstrated by the compounds. Elasterol and 2-methylcholestan-3-ol dramatically reduced the levels of HSP70 and HSP90 expression, whereas THC and cannabinol successfully reduced the expression of MMPs and TNF-α. Potential therapeutic benefits are suggested by this enhancement.

Graphical abstract
Keywords
Ovarian cancer
Phytocompounds
HSP-70
MMP’s
Molecular Docking
Protein dynamic simulation
Funding
None.
Conflict of interest
The authors declare that they have no competing interests.
References
  1. Cintantya DT, Sandhika W. Genetic Mutation Assay in Ovarian Cancer Patient. International Journal of Scientific Advances. 2023.

 

  1. Brewer G. Obesity as a promoter in BRCA mutation carriers. Nature Reviews Cancer. 2023;23(5):272-.

 

  1. Wei J-J, William J, Bulun S. Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects. International Journal of Gynecological Pathology. 2011;30(6):553-68.

 

  1. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA: a cancer journal for clinicians. 2018;68(4):284-96.

 

  1. McKee M, Dunnell K, Anderson M, Brayne C, Charlesworth A, Johnston-Webber C, et al. The changing health needs of the UK population. The Lancet. 2021;397(10288):1979-91.

 

  1. Holtedahl K, Hjertholm P, Borgquist L, Donker GA, Buntinx F, Weller D, et al. Abdominal symptoms and cancer in the abdomen: prospective cohort study in European primary care. British Journal of General Practice. 2018;68(670):e301-e10.

 

  1. Galaal K, Donkers H, Bryant A, Lopes AD. Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database of Systematic Reviews. 2018(10).

 

  1. Cleanclay WD, Zakari S, Adigun TO, Ayeni TO, Nnaji PC, Nnenna AD, et al. Cancer Biology and Therapeutics: Navigating Recent Advances and Charting Future Directions. Tropical Journal of Natural Product Research. 2023;7(12).

 

  1. Baskar R, Dai J, Wenlong N, Yeo R, Yeoh K. Biological response of cancer cells to radiation treatment. Frontiers in molecular biosciences, 1, 24. View in Scopus. 2014:24.

 

  1. Lalremmawia H, Tiwary BK. Identification of molecular biomarkers for ovarian cancer using computational approaches. Carcinogenesis. 2019;40(6):742-8.

 

  1. Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. Journal for immunotherapy of cancer. 2016;4:1-25.

 

  1. Cheng T, Pan Y, Hao M, Wang Y, Bryant SH. PubChem applications in drug discovery: a bibliometric analysis. Drug discovery today. 2014;19(11):1751-6.

 

  1. Zahid S, Malik A, Waqar S, Zahid F, Tariq N, Khawaja AI, et al. Countenance and implication of Β-sitosterol, Β-amyrin and epiafzelechin in nickel exposed Rat: in-silico and in-vivo approach. Scientific Reports. 2023;13(1):21351.

 

  1. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific reports. 2017;7(1):42717.

 

  1. Banerjee P, Kemmler E, Dunkel M, Preissner R. ProTox 3.0: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Research. 2024:gkae303.

 

  1. Arora T, Mullangi S, Lekkala MR. Ovarian cancer. 2021.

 

  1. Shafabakhsh R, Asemi Z. Quercetin: a natural compound for ovarian cancer treatment. Journal of ovarian research. 2019;12:1-9.

 

  1. Maioru O-V, Radoi V-E, Coman M-C, Hotinceanu I-A, Dan A, Eftenoiu A-E, et al. Developments in genetics: better management of ovarian cancer patients. International Journal of Molecular Sciences. 2023;24(21):15987.

 

  1. Szamreta EA, Wang W-J, Shah R, Corman S, Monberg M. The burden of ovarian cancer in the USA from 2007 to 2018: evidence from the Medical Expenditure Panel Survey. Future Oncology. 2023;19(19):1331-42.

 

  1. Li, Xi et al. “Curcumin suppresses malignant behaviors of ovarian cancer through regulation of tumor-associated macrophages.” Medical oncology (Northwood, London, England) vol. 42,5 151. 5 Apr. 2025. doi: 10.1007/s12032-025-02682-9

 

  1. Ameer SF, Mohamed MY, Elzubair QA, Sharif EAM and Ibrahim WN (2024) Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionize cancer treatment? Front. Oncol. 14:1438040. doi: 10.3389/fonc.2024.1438040

 

  1. Kumar, K., Bosch, K., Vemuri, V. et al. Withaferin A ameliorates ovarian cancer-induced renal damage through the regulation of expression of inflammatory cytokines. J Ovarian Res 17, 199 (2024). doi: 10.1186/s13048-024-01519-9

 

  1. Thaklaewphan P, Wikan N, Potikanond S, Nimlamool W. Oxyresveratrol Enhances the Anti-Cancer Effect of Cisplatin against Epithelial Ovarian Cancer Cells through Suppressing the Activation of Protein Kinase B (AKT). Biomolecules. 2024; 14(9):1140. doi: 10.3390/biom14091140

 

  1. Li, Xiaoli et al. “S100A4/NF-κB axis mediates the anticancer effect of epigallocatechin-3-gallate in platinum-resistant ovarian cancer.” iScience vol. 27,2 108885. 12 Jan. 2024, doi: 10.1016/j.isci.2024.108885

 

  1. Zhang, X., Xiong, B., Cheng, Y., Huang, J., Xue, J., Li, X., Lu, W., Zhu, J., Wang, L., Yang, W., & Cheng, Z. (2025). Berberine inhibits metastasis of ovarian cancer by blocking lipid metabolism, alleviating aging of adipose tissue and increasing tumor infiltrating immune cells. Translational oncology, 56, 102380. doi: 10.1016/j.tranon.2025.102380

 

  1. Gullo G, Cucinella G, Chiantera V, Dellino M, Cascardi E, Török P, Herman T, Garzon S, Uccella S, Laganà AS. Fertility-Sparing Strategies for Early-Stage Endometrial Cancer: Stepping towards Precision Medicine Based on the Molecular Fingerprint. International Journal of Molecular Sciences. 2023; 24(1):811. doi: 10.3390/ijms24010811

 

  1. Gullo, G et al. “Myo-inositol: from induction of ovulation to menopausal disorder management.” Minerva ginecologica vol. 67,5 (2015): 485-6.
Share
Back to top
Cancer Plus, Electronic ISSN: 2661-3840 Print ISSN: 2661-3832, Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept